Glucagon Research: What 65,985 Studies Show (2026) | RetatrutideCompare

Glucagon — 65,985 studies indexed on PubMed. Activates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose. Half-life: ~3–6 minutes. FDA status: FDA-approved (multiple formulations).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Glucagon?

There are approximately 65,985 studies indexed on PubMed that mention Glucagon (GlucaGen, Baqsimi), based on a search last updated 2026-06-18.

Is Glucagon FDA-approved?

FDA status: FDA-approved (multiple formulations).

How does Glucagon work?

Activates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose.

Reference facts

Also known as: GlucaGen, Baqsimi, Gvoke
Category: GLP-1 & Metabolic
Mechanism of action: Activates the glucagon receptor on hepatocytes, driving glycogenolysis and gluconeogenesis to raise blood glucose.
Targets: GCGR
Indications under research or approved: Severe Hypoglycemia, Diagnostic adjunct in radiology
Regulatory status (reference entry): FDA-approved (multiple formulations)
Half-life: ~3–6 minutes
Sequence: HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
Sequence notes: 29-residue counter-regulatory peptide hormone secreted by pancreatic alpha cells.
Molecular weight (Da): 3485
PDB accession: 1GCN
Originator / sponsor: Eli Lilly, Novo Nordisk, Xeris
First reported: 1923

Primary References

Baqsimi (nasal glucagon) FDA label

Explore research articles about Glucagon

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.